Claims
- 1. A compound of Formula I or a pharmaceutically acceptable salt thereof: wherein:Ar is unsubstituted or substituted phenyl, the substituents are selected from the group F, Cl, Br, I, CN, NO2, OCH3, OC(O)CH3, CF3, OCH2CH2OH or N(CH3)2; E is hydrogen; wherein m is an integer of from 1 to 3;R is hydrogen, methyl, H2NC(O)alkyl, alkenylalkyl, heteroaralkyl, (C3-C7 cycloalkyl)alkyl, or C(O)CH3; Y is OH; X is hydrogen; and * denotes trans.
- 2. A compound according to claim 1 selected from:trans-4-[3-(4Phenylcyclohexylamino)propyl]phenol; trans-4-[(1S,2S)-1-Hydroxy-2(4-phenylcyclohexylamino)prophyl]phenol; trans-4-{2[4-(4-Flurophenyl)-4-hydroxycyclohexylamino]ethyl}phenol; trans-4-{3[Methyl(4-phenylcyclohexy)amino]prophyl}phenol; trans-4-[(4Phenylcyclohexylamino)ethyl]phenol trans-4-{2[Methyl(4phenylcyclohexyl)amino]ethyl}phenol; trans-4-[4-(4Phenylcyclohexylamino)butyl]phenol; and trans-4-{4-[Methyl(4-phenylcycloheyl)amino]butyl}phenol.
- 3. A pharmaceutical composition useful for treating disorders responsive to the selective blockade of N-menthyl-D-aspartate receptor subtypes in a mammal, including a human, optionally disorders as stroke, cerebral ischemia, trauma, hypoglycemia, neurodegenerative disorders, anxiety, depression, migraine headache, convulsions, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence the compositions comprising a pharmaceutically acceptable carrier, excipient, or diluent and a therapeutically effective amount of at least one compound of claim 1.
- 4. The pharmaceutical composition according to claim 3, wherein the neurodegenerative disorder is Parkinson's disease.
- 5. A method for treating disorders responsive to the selective blockade of N-metbyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom which comprises administering in unit dosage form at least one compound represented by Formula I of claim 1.
- 6. The method according to claim 5, wherein the disorder is Parkinson's disease.
- 7. The method according to claim 6, further comprising administering in unit dosage form a compound of Formula I to a mammal suffering from Parkinson's disease.
Parent Case Info
This application is a §371 filing of PCT/US01/15349 filed May 14, 2001, which claims benefit of U.S. Provisional Application 60/208,703 filed Jun. 1, 2000; the entire contents of each of which are hereby incorporated herein by reference.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/15349 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/92204 |
12/6/2001 |
WO |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
4438020 |
May 1996 |
DE |
0940387 |
Sep 1999 |
EP |
0982026 |
Mar 2000 |
EP |
0000197 |
Jan 2000 |
WO |
Non-Patent Literature Citations (2)
Entry |
PCT International Search Report, PCT/US01/15349. |
Cantarelli et al., “Fenilcicloesilammine E Derivati Nota III—3-e 4-fenilcicloesilammine mono-e disostituite all'azoto. Loro attivita anestetica locale e pressoria”, Il Farmaco, vol. 25, No. 4, 1970, pp. 248-294. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/208703 |
Jun 2000 |
US |